Computationally motivated synthesis and enzyme kinetic evaluation of N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors

Jaida Begum, Gergely Varga, T. Docsa, P. Gergely, Joseph M. Hayes, László Juhász, L. Somsák

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Following our recent study of N-(β-d-glucopyranosyl)oxadiazolecarboxamides (Polyák et al., Biorg. Med. Chem. 2013, 21, 5738) revealed as moderate inhibitors of glycogen phosphorylase (GP), in silico docking calculations using Glide have been performed on N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides with different aryl substituents predicting more favorable binding at GP. The ligands were subsequently synthesized in moderate yields using N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-tetrazole-5-carboxamide as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b (RMGPb) revealed the ligands to be low μM GP inhibitors; the phenyl analogue (Ki = 1 μM) is one of the most potent N-(β-d-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of the GP catalytic site discovered to date. Based on QM and QM/MM calculations, the potency of the ligands is predicted to arise from favorable intra- and intermolecular hydrogen bonds formed by the most stable solution phase tautomeric (t2) state of the 1,2,4-triazole in a conformationally dynamic system. ADMET property predictions revealed the compounds to have promising pharmacokinetic properties without any toxicity. This study highlights the benefits of a computationally led approach to GP inhibitor design. This journal is

Original languageEnglish
Pages (from-to)80-89
Number of pages10
JournalMedChemComm
Volume6
Issue number1
DOIs
Publication statusPublished - Jan 1 2015

Fingerprint

Glycogen Phosphorylase
Enzyme kinetics
Enzymes
Ligands
Phosphorylase b
Pharmacokinetics
Computer Simulation
Toxicity
Muscle
Hydrogen
Catalytic Domain
Hydrogen bonds
Dynamical systems
Rabbits
Muscles

ASJC Scopus subject areas

  • Biochemistry
  • Pharmaceutical Science

Cite this

Computationally motivated synthesis and enzyme kinetic evaluation of N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors. / Begum, Jaida; Varga, Gergely; Docsa, T.; Gergely, P.; Hayes, Joseph M.; Juhász, László; Somsák, L.

In: MedChemComm, Vol. 6, No. 1, 01.01.2015, p. 80-89.

Research output: Contribution to journalArticle

@article{4e2ed13121fd430588cf8896d072b7c9,
title = "Computationally motivated synthesis and enzyme kinetic evaluation of N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors",
abstract = "Following our recent study of N-(β-d-glucopyranosyl)oxadiazolecarboxamides (Poly{\'a}k et al., Biorg. Med. Chem. 2013, 21, 5738) revealed as moderate inhibitors of glycogen phosphorylase (GP), in silico docking calculations using Glide have been performed on N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides with different aryl substituents predicting more favorable binding at GP. The ligands were subsequently synthesized in moderate yields using N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-tetrazole-5-carboxamide as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b (RMGPb) revealed the ligands to be low μM GP inhibitors; the phenyl analogue (Ki = 1 μM) is one of the most potent N-(β-d-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of the GP catalytic site discovered to date. Based on QM and QM/MM calculations, the potency of the ligands is predicted to arise from favorable intra- and intermolecular hydrogen bonds formed by the most stable solution phase tautomeric (t2) state of the 1,2,4-triazole in a conformationally dynamic system. ADMET property predictions revealed the compounds to have promising pharmacokinetic properties without any toxicity. This study highlights the benefits of a computationally led approach to GP inhibitor design. This journal is",
author = "Jaida Begum and Gergely Varga and T. Docsa and P. Gergely and Hayes, {Joseph M.} and L{\'a}szl{\'o} Juh{\'a}sz and L. Soms{\'a}k",
year = "2015",
month = "1",
day = "1",
doi = "10.1039/c4md00335g",
language = "English",
volume = "6",
pages = "80--89",
journal = "MedChemComm",
issn = "2040-2503",
publisher = "Royal Society of Chemistry",
number = "1",

}

TY - JOUR

T1 - Computationally motivated synthesis and enzyme kinetic evaluation of N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides as glycogen phosphorylase inhibitors

AU - Begum, Jaida

AU - Varga, Gergely

AU - Docsa, T.

AU - Gergely, P.

AU - Hayes, Joseph M.

AU - Juhász, László

AU - Somsák, L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Following our recent study of N-(β-d-glucopyranosyl)oxadiazolecarboxamides (Polyák et al., Biorg. Med. Chem. 2013, 21, 5738) revealed as moderate inhibitors of glycogen phosphorylase (GP), in silico docking calculations using Glide have been performed on N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides with different aryl substituents predicting more favorable binding at GP. The ligands were subsequently synthesized in moderate yields using N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-tetrazole-5-carboxamide as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b (RMGPb) revealed the ligands to be low μM GP inhibitors; the phenyl analogue (Ki = 1 μM) is one of the most potent N-(β-d-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of the GP catalytic site discovered to date. Based on QM and QM/MM calculations, the potency of the ligands is predicted to arise from favorable intra- and intermolecular hydrogen bonds formed by the most stable solution phase tautomeric (t2) state of the 1,2,4-triazole in a conformationally dynamic system. ADMET property predictions revealed the compounds to have promising pharmacokinetic properties without any toxicity. This study highlights the benefits of a computationally led approach to GP inhibitor design. This journal is

AB - Following our recent study of N-(β-d-glucopyranosyl)oxadiazolecarboxamides (Polyák et al., Biorg. Med. Chem. 2013, 21, 5738) revealed as moderate inhibitors of glycogen phosphorylase (GP), in silico docking calculations using Glide have been performed on N-(β-d-glucopyranosyl)-1,2,4-triazolecarboxamides with different aryl substituents predicting more favorable binding at GP. The ligands were subsequently synthesized in moderate yields using N-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-tetrazole-5-carboxamide as starting material. Kinetics experiments against rabbit muscle glycogen phosphorylase b (RMGPb) revealed the ligands to be low μM GP inhibitors; the phenyl analogue (Ki = 1 μM) is one of the most potent N-(β-d-glucopyranosyl)-heteroaryl-carboxamide-type inhibitors of the GP catalytic site discovered to date. Based on QM and QM/MM calculations, the potency of the ligands is predicted to arise from favorable intra- and intermolecular hydrogen bonds formed by the most stable solution phase tautomeric (t2) state of the 1,2,4-triazole in a conformationally dynamic system. ADMET property predictions revealed the compounds to have promising pharmacokinetic properties without any toxicity. This study highlights the benefits of a computationally led approach to GP inhibitor design. This journal is

UR - http://www.scopus.com/inward/record.url?scp=84920396259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920396259&partnerID=8YFLogxK

U2 - 10.1039/c4md00335g

DO - 10.1039/c4md00335g

M3 - Article

AN - SCOPUS:84920396259

VL - 6

SP - 80

EP - 89

JO - MedChemComm

JF - MedChemComm

SN - 2040-2503

IS - 1

ER -